1
|
Ramalho S, Silva I, Amaral M, Farinha C. 633: Characterization of 4 rare CFTR trafficking mutants and their response to rescue strategies. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02056-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Ramalho S, Claggett B, Kitzman D, Chang P, Cipriano Junior G, Solomon S, Skali H, Shah A. Obstructive and restrictive ventilatory patterns are differentially associated with cardiac structure and function in late-life. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Pulmonary and cardiac function both decline with age. However, few data exist regarding the associations of obstructive and restrictive spirometric patterns with cardiac structure and function in late-life.
Purpose
Determine the associations of reduced percent predicted forced vital capacity (ppFVC) and forced expired volume in 1 second (FEV1)/FVC with cardiac structure and function in late life.
Methods
In the Atherosclerosis Risk in Communities longitudinal cohort study, 3,854 heart failure free participants underwent echocardiography and spirometry at the fifth study visit (2011–2013). Relationships were examined using multivariable linear regression. Models adjusted for demographics and clinical risk factors (Table legend).
Results
Mean age was 75±5 years, 40% were male, 19% black, and 6% current smokers. Mean FEV1/FVC was 72±8, and ppFVC was 98±17%. In adjusted analyses, lower FEV1/FVC was associated with higher pulmonary arterial pressure (PASP) but not with measures of left ventricular (LV) structure or function (Table). In contrast, lower ppFVC, was associated with greater LV mass, worse LV strain, higher E/e' ratio, greater left atrial volume index, and higher PASP (all p<0.01; Table).
Conclusion
In late life, reductions in both FEV1/FVC and ppFVC are associated with higher pulmonary pressure, but only ppFVC was associated with worse LV structure and function.
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services
Collapse
Affiliation(s)
- S Ramalho
- Sarah Network of Rehabilitation Hospitals, Brasilia, Brazil
| | - B.L Claggett
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| | - D.W Kitzman
- Wake Forest University, School of Medicine, Winston-Salem, United States of America
| | - P.P Chang
- University of North Carolina, School of Medicine, Chapel Hill, United States of America
| | - G Cipriano Junior
- University of Brasilia, Health Sciences and Technologies Program, Brasilia, Brazil
| | - S.D Solomon
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| | - H.L Skali
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| | - A.M Shah
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| |
Collapse
|
3
|
Ramalho S, Claggett B, Kitzman D, Chang P, Cipriano Junior G, Solomon S, Skali H, Shah A. Differential impact of obstructive and restrictive ventilatory patterns on incident heart failure with preserved versus reduced ejection fraction in late-life. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Subclinical pulmonary dysfunction predicts cardiovascular (CV) outcomes, especially heart failure (HF). However, the impact of reduced percent predicted forced vital capacity (ppFVC) and forced expired volume in 1 second (FEV1)/FVC on different incident HF phenotypes in late-life is unclear.
Purpose
Determine the associations of FEV1/FVC and ppFVC with incident HF with preserved (HFpEF) and reduced (HFrEF) ejection fraction in late-life.
Methods
In the Atherosclerosis Risk in Communities longitudinal cohort study, 3,854 HF-free participants who underwent echocardiography and spirometry at the fifth study visit (2011–2013). The relation between pulmonary function and incident adjudicated HFpEF and HFrEF were examined using multivariable Cox proportional hazards models adjusted for demographics, body mass index, coronary artery disease, atrial fibrillation, hypertension, diabetes, and NT-proBNP.
Results
Mean age was 75±5 years, 40% were male, 19% black, and 6% current smokers. Mean FEV1/FVC was 72±8, and ppFVC was 98±17%. At a median follow-up of 5.6 years, lower ppFVC was independently associated with incident HFpEF, but not HFrEF (Table). Lower FEV1/FVC ratio was associated with higher risk of incident HFrEF but not HFpEF in models adjusted for demographics, which did not persist after further adjustment for clinical risk factors.
Conclusion
The relationships of reduced ppFVC and FEV1/FVC with incident HF differ significantly by HF phenotype.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services
Collapse
Affiliation(s)
- S Ramalho
- Sarah Network of Rehabilitation Hospitals, Brasilia, Brazil
| | - B.L Claggett
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| | - D.W Kitzman
- Wake Forest University, School of Medicine, Winston-Salem, United States of America
| | - P.P Chang
- University of North Carolina, School of Medicine, Chapel Hill, United States of America
| | - G Cipriano Junior
- University of Brasilia, Health Sciences and Technologies Program, Brasilia, Brazil
| | - S.D Solomon
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| | - H Skali
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| | - A.M Shah
- Brigham and Women'S Hospital, Harvard Medical School, Cardiovascular division, Boston, United States of America
| |
Collapse
|
4
|
Henriques C, Caceiro E, Santos M, Ramalho S. AAS - Affect, love and sexuality for a sample of young Portuguese students. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz034.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- C Henriques
- School of Health, Polytechnic Institute of Leiria, Portugal
| | - E Caceiro
- School of Health, Polytechnic Institute of Leiria, Portugal
| | - M Santos
- School of Health, Polytechnic Institute of Leiria, Portugal
| | - S Ramalho
- School of Health, Polytechnic Institute of Leiria, Portugal
| |
Collapse
|
5
|
Ramalho S, Natal R, Cardoso Filho C, Xavier MB, da Silva AER, Silva LR, Vasconcelos V, Reinert T, Coelho GP, Silva GR, dos Santos CC. Abstract P1-15-16: Pathological complete response rates with the addition of carboplatin to standard neoadjuvant chemotherapy in a cohort of real–world patients with triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-15-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Addition of carboplatin to standard neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC) remains controversial. There are several randomized trials showing that carboplatin increases the likelihood of achieving pathological complete response (pCR) in TNBC. Patients with TNBC who achieve pCR has been shown to have better disease-free and overall survival. The aim of this study was to asses the impact of adding carboplatin to standard NACT in TNBC in terms of pCR rates and toxicity. Methods:In this cross-sectional study, 252 consecutive patients with primary TNBC who were submitted to neoadjuvant chemotherapy between 2013 and 2018, in a single center, were selected. Patients with biopsy-confirmed TNBC, previously untreated, with clinical stages I-III were included (n=179). Clinical pathological features, pathological response, treatment protocol, and toxicities were analyzed and considered for statistical analysis. Eighty patients treated from 2013 to 2015 received doxorubicin plus cyclophosphamide once every 3 weeks (AC) for four cycles, followed by 12 weeks (wP) or every 3 weeks (P) paclitaxel(AC-T group). Ninety-nine patients, treated from 2015 to 2018 had four cycles of AC followed by wP plus weekly carboplatin (Cb) area under curve (AUC) 1.5-2.0 (AC-TCb group). Pathologic response was determined locally, and pCR was defined as the absence of residual invasive disease with or without ductal carcinoma in situ in the breast and axilla. Results: Data from 179 patients were included in the analysis (AC-T: n=80; AC-TCb: n=99). Patients in AC-TCb group had a median age of 51.7 years vs. 47.4 years in AC-T group, p=0.01. In AC-TCb group 61.6% of patients were postmenopausal vs 43.7% in AC-T group, p=0.03. The distribution of clinical stage in groups AC-TCb and AC-T were as follows: stage I 6.0% vs 0%; stage II 42.4% vs 43.7%; stage III 51.6% vs 56.3%, respectively (p=0.02). In AC-TCbgroup, 34 patients (35.0%) had pCR in comparison to 20 patients (25.0%) on AC-T group (p=0.22). Pathological stage distribution in groups AC-TCb and AC-T were: stage I 24.7% vs 33.7%; stage II 23.7% vs 26.3%; stage III 16.4% vs 15%, respectively (p=0.42). More than 85.0% of patients in AC-TCb group received at least 9 weeks of carboplatin and less than 20.0% required dose reduction due to toxicity.Conclusions: An improved pathological complete response for TNBC patients submitted to standard NACT plus carboplatin was observed. The results are in accordance with previous studies demonstrating that the addition of carboplatin to NACT improves pCR rate in TNBC with a favorable risk to benefit profile. Therefore carboplatin might be a potential component of NACT and should be considered in this context.
Distribution of patients with TNBC submitted to NACT with AC-T and AC-TCb according clinical–pathological characteristicsClinical pathological characteristicsAC-T n= 80AC-TCb n=99pMenopausal 0.03yes3561 no4538 Clinical stage 0.02I06 II3542 III4551 Histologic type 0.25IDC8096 others03 Histologic grade 0.86101 22932 35164 Pathological stage 0.42O2034 I2724 II2123 III1216 pCR 0.22yes2034 no6063
Citation Format: Ramalho S, Natal RdA, Cardoso Filho C, Xavier MB, da Silva AER, Silva LR, Vasconcelos V, Reinert T, Coelho GP, Silva GRdP, dos Santos CC. Pathological complete response rates with the addition of carboplatin to standard neoadjuvant chemotherapy in a cohort of real–world patients with triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-15-16.
Collapse
Affiliation(s)
- S Ramalho
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - RdA Natal
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - C Cardoso Filho
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - MB Xavier
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - AER da Silva
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - LR Silva
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - V Vasconcelos
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - T Reinert
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - GP Coelho
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - GRdP Silva
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| | - CC dos Santos
- Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; Laboratory of Investigative Pathology, Women's Hospital (CAISM), State University of Campinas(UNICAMP), Campinas, São Paulo, Brazil; Pos Graduated Program - Faculty of Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Rio Grande do Sul, Brazil; Grupo Diagnose Patologia e Biologia Molecular, Caxias do Sul, Rio Grande do Sul, Brazil
| |
Collapse
|
6
|
Abstract
Abstract
Introduction: The Oncotype DX was associated to 14% of adjuvant chemotherapy administration to Hormonal Receptor positive (HR+) and HER2 negative, T1N0 or T2N0 breast cancer patients at Tailor X trial recently published (RS>25)
Objective: To describe the adjuvant chemotherapy administration to a Brazilian public hospital for HR+ HER2 negative, T1N0 or T2N0 breast cancer patients. And the estimate the cost effectivity of Oncotype DX in our low income scenary.
Materials and Methods:This retrospective cross-sectional study was conducted at the Oncology Division of the Women's Hospital - CAISM of the State University of Campinas (UNICAMP), Brazil. All patient data were found from the hospital records from 2007 to 2009. It was included T1N0 and T2N0 HR+/HER2 negative breast cancer patients. Patients submitted to neoadjuvant treatment were excluded.
We calculate the final cost of different types of chemotherapy used and the potential impact to oncotype DX introduction in this scenary.
Results: It was found 109 patients records. 66% (72/109) had received adjuvant chemotherapy. 35% (38/109) had AC (X6), 29% (32/109) had CMF (X6) and 2% (2/109) had AC-T (X4). The total cost for chemotherapy scheme were; AC (X6) US$ 346,9; CMF (X6), US$300,6; ACT (X4), US$395,9. The total cost of chemotherapy was US$ 23.596,83 to 72 patients. If we consider 14% (15/109) of adjuvant chemotherapy associate to a Oncotype DX use (Tailor X RS>25), It would reduce adjuvant chemotherapy administration to 15 patients. The chemotherapy cost would be US$ 4588,27. In our scenary, It could save US$ 19.008,56. Nevertheless, the Oncotype Dx cost to Brasil is US$ 3.200,00 for each test. To 109 patients the total cost would be (109 X US$ 3.200,00) US$ 348.800,00. Therefore, the total cost for Oncotype DX program plus adjuvant chemotherapy for our patients would be US$ 348.800,00 + US$ 4.588,27= US$ 353.388,27. While in the real situation we had spent US$ 23.596,83. The total estimate cost would be 15 times more.
Conclusion: At the moment, because of the assay high cost and the low cost of the adjuvant chemotherapy to HR+, HER2 negative T1N0 and T2N0, It would be difficult to consider Oncotype DX cost-effective to Brazilian public heath system. Even considering many advantages to spare chemotherapy to this population.
Citation Format: Cabello C, de Andrade RN, Cabello TF, Teixeira S, da Costa LS, Ramalho S. Oncotype DX cost effectivity to a Brazilian public hospital [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-15-04.
Collapse
Affiliation(s)
- C Cabello
- State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
| | - RN de Andrade
- State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
| | - TF Cabello
- State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
| | - S Teixeira
- State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
| | - LS da Costa
- State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
| | - S Ramalho
- State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil
| |
Collapse
|
7
|
Teixeira SRC, Camargo HSA, Ramalho S, Natal R, Machado H, Camargo MMA, Azevedo J, Arruda M, Negrão EMS, Almeida NR, Teixeira AL, Cabello V, Cabello C. Abstract P4-02-09: Breast cancer and magnetic resonance imaging (MRI): Background parenchymal enhancement (BPE) predicting response to neoadjuvant chemotherapy (NAC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-02-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective: To assess the association of MRI BPE and pathological response in women diagnosed with stage II/III breast cancer submitted to NAC. Methods: This observational and cross-sectional retrospective study was performed in consecutive women who underwent NAC and had MRI exams before and after chemotherapy. The MRI was done before and after 2 weeks of completing NAC. BPE was classified according to ACR-BIRADS 5th edition. The type of BPE before NAC, its changes and the relationship to total pathologic complete response (TpCR) were evaluated. Data were paired with patient age, size on MRI before and after NAC, features of clinical response according to the RECIST criteria, tumor grade and immunohistochemical (IHC) subtypes. MRI assessment included amount of fibroglandular tissue, symmetry of BPE and measurement of tumor at the longest diameter. All images were blinded reviewed by a radiologist. We used for the changes of the BPE the Bowker symmetry test or the McNemar test and to analyze the factors related to the clinical and pathologic responses, logistic regression analysis. The level of significance adopted was 5% (p<0.05). Results: We studied 71 women between 2009 and 2016. The medium age was 37 years old. BPE was symmetrical in 68 women (95.8%). Moderate and marked BPE was present in 28 (39.4%) of the affected breasts and in 25 (34.2%) of the contralateral breasts. After NAC all BPE were symmetrical and just 3% of them were moderate or marked. Regarding the IHC subtype, 40 women (56.3%) were triple negative or HER2 positive, and these women had a higher frequency of TpCR (55% for each, compared to 12.9% in patients with luminal subtypes). We found to be independently associated with pCR: the reduction of BPE (in the affected or contralateral breast) and the molecular subtypes triple negative and HER2 positive
Table 1. Multivariate Analysis related to TpCR (n=71).VariableCategoryP-ValueO.R.*CI 95% O.R.*Tumor Size on MR pre-MAC (cm) 0.1710,8590.691-1.068Luminal subtypeLuminal B (ref.)---1.00--- Luminal A0.3120.450.10-2.11 HER2pos/ Luminal B HER20.0055.781.71-19.58 Triple negative0.0493.271.01-10.64Age (years) 0.3870.9820.942-1.023Nottingham grade1 (ref.)---1.00--- 20.0817.830.78-79.16 30.0967.100.71-71.31BPE pre-NAC (S or A)Asymmetric (ref.)---1.00--- Symmetric0.3273.030.33-27.76BPE pre-NAC affected breastMinimal (ref.)---1.00--- Mild0.8120.860.24-3.09 Moderate0.3711.890.47-7.64 Marked0.5911.570.30-8.17BPE pre-NAC contralateral breastMinimal (ref.)---1.00--- Mild0.7130.790.22-2.81 Moderate0.2502.330.55-9.77 Marked0.4701.880.34-10.43BPE ChangeSame/increased (ref.)---1.00--- Reduction0.0263.011.14-7.96* OR (Odds Ratio) = Risk ratio to pCR; (n=26 pCR, n=7 DpCR, n=31 PR e n=7 ED, where Total pCR is pathological complete response (without invasive and DCIS in the breast and axilla) DpCR is pathological response with just DCIS, PR is partial response and ED is stable disease – we haven't progression disease). CI 95% OR = Confidence interval of 95% to risk ratio. Ref.: reference level. Proportional risk models.
Conclusion: BPE reduction was significantly associated with TpCR. Nevertheless, patterns of BPE pre-NAC have no association with pathological response.
Citation Format: Teixeira SRC, Camargo HSAd, Ramalho S, Natal R, Machado HdC, Camargo MMAd, Azevedo J, Arruda MdS, Negrão EMS, Almeida NR, Teixeira AL, Cabello V, Cabello C. Breast cancer and magnetic resonance imaging (MRI): Background parenchymal enhancement (BPE) predicting response to neoadjuvant chemotherapy (NAC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-02-09.
Collapse
Affiliation(s)
- SRC Teixeira
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - HSAd Camargo
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - S Ramalho
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - R Natal
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - HdC Machado
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - MMAd Camargo
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - J Azevedo
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - MdS Arruda
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - EMS Negrão
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - NR Almeida
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - AL Teixeira
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - V Cabello
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| | - C Cabello
- UNICAMP - State University of Campinas, Campinas, Sao Paulo, Brazil; CDE Diagnóstico por Imagem, Campinas, Sao Paulo, Brazil
| |
Collapse
|
8
|
NematiShafaee M, Natal RA, Ramalho S, Dória MT, Conz L, Cabello V, Pavanello M, Mano MS, Linck RDM, Batista LS, Pedro EP, Bines J, de Paula BH, Zucca-Matthes G, Bondy ML, Ellis MJ, Podany E, Debord L, Makawita S, Stewart K, Cabello C. Abstract P4-10-15: Impact of delay in breast cancer diagnosis and treatment according to health insurance status in southwest Brazil and Houston, Texas. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-10-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Access to medical care vary across the world and is related to different health systems with an impact in recurrence.Objective: To evaluate disparities in breast cancer(BC) diagnosis and treatment between public and private services in southwest Brazil and at two public safety net hospitals in Houston, Texas.Methods: Women diagnosed with BC stages I-III between 2009 to 2011, and treated at the four hospitals in Brazil and two health centers in US were included. All statistical analyses were performed in R studio software, and p<0.05 was considered significant.Results: 1245 women were included: 967 from public health system (PHS) (20.3% from Houston, Texas) and 274 from private system(PS). Recurrence rate was higher in PHS (14.6% vs. 2.6%, p<0.001)
Table 1. Clinical and demographic characteristics of the patientsCharacteristicsPublic (%), n=967Private (%), n=274pDiscovery of BC By patient530 (54.8)92 (33.5) Routine exam87 (9)109 (39.8) Screening mammography270 (27.9)23 (8.4) Other80 (8.3)50 (18.3)<0.001Initial treatment Surgery687 (71)241 (88) Neo-adjuvant chemotherapy224 (23.2)27 (9.8) Neo-adjuvant hormone therapy23 (2.3)27 (9.8) Not available33 (3.4)3 (1.1)<0.001Clinical Stage I293 (30.3)113 (41.2) II342 (35.4)52 (19) III271 (28)15 (5.5) Unknown61 (6.3)94 (34.3)<0.001Subtype HR+/HER2 -561 (58)192 (70.1) HR-/HER2+108 (11.1)29 (10.6) HR-/HER2+76 (7.9)14 (5.1) Triple negative149 (15.4)28 (10.2) Unknown73 (7.6)11 (4)0.012Symptomatic at Diagnosis Yes591 (61.1)100 (36.5) No306 (31.6)97 (35.4) Unknown70 (7.2)77 (28.1)<0.001Recurencen=772n=146 No719 (74.4)193 (70.4) Yes142 (14.6)7 (2.6) Unknown106 (11)74 (27)<0.001
. Considering the interval in weeks: symptoms to diagnosis, diagnosis to first treatment (either surgery or neoadjuvant chemotherapy), diagnosis to first systemic treatment, diagnosis to surgical treatment and diagnosis to radiotherapy were longer in public patients (24.1 vs. 8.7; 11.1 vs. 3.5; 18.6 vs. 9.8; 16.9 vs. 5.6; 51.4 vs. 26.1; p<0.001).
Table 2. Delay disparities between public and private health system PublicPrivatepSymptoms to diagnosis Number of patients575146 Time (weeks)24.1 (0.4-104.9)8.7 (0.0-43.7)<0.001Diagnosis to first treatment Number of patients663180 Time (weeks)11.1 (2.0-31.5)3.5 (0.0-11.0)<0.001Diagnosis to first systemic treatment Number of patients526106 Time (weeks)18.6 (2.6-44.7)9.8 (1.9-29.3)<0.001Diagnosis to surgical treatment Number of patients657178 Time (weeks)16.9 (3.4-45.6)5.6 (0.0-32.9)<0.001Diagnosis to radiotherapy Number of patients465127 Time (weeks)51.4 (18.7-88.4)26.1 (5.6-66.4)<0.001
In multivariate analysis, PHS (HR 1.72; 95% CI 1.34-1.88; p adj=0.003), presence of symptoms (HR 2.29; 95% CI 1.39-3.78; p adj=0.001), clinical stage III (HR 1.62; 95% CI 1.35-1.93; p adj<0.001), and triple negativity and HER2neu positivity (1.18; 95% CI 1.03-1.35; p adj=0.021) were all associated with a higher recurrence rate.Conclusions: There were significant disparities between PHS and PS. Women in the PHS presented higher rates of recurrence, advanced clinical stages at diagnosis, symptoms and more aggressive subtypes by IHC. additionally, the interval between symptoms to diagnosis and diagnosis to treatments was longer in PHS.
Citation Format: NematiShafaee M, Natal RA, Ramalho S, Dória MT, Conz L, Cabello V, Pavanello M, Mano MS, Linck RDM, Batista LS, Pedro EP, Bines J, de Paula BH, Zucca-Matthes G, Bondy ML, Ellis MJ, Podany E, Debord L, Makawita S, Stewart K, Cabello C. Impact of delay in breast cancer diagnosis and treatment according to health insurance status in southwest Brazil and Houston, Texas [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-10-15.
Collapse
Affiliation(s)
- M NematiShafaee
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - RA Natal
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - S Ramalho
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - MT Dória
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - L Conz
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - V Cabello
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - M Pavanello
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - MS Mano
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - RDM Linck
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - LS Batista
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - EP Pedro
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - J Bines
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - BH de Paula
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - G Zucca-Matthes
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - ML Bondy
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - MJ Ellis
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - E Podany
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - L Debord
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - S Makawita
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - K Stewart
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| | - C Cabello
- Baylor College of Medecine, Houston, TX; State University of Campinas, Campinas, Sao Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil; Brazilian National Cancer Institute, Rio de Janeiro, Brazil; Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
| |
Collapse
|
9
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd8-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Dysregulation of the estrogen receptor gene (ESR1) is an established mechanism of inducing endocrine therapy resistance. We previously discovered a chromosomal translocation event generating an estrogen receptor gene fused in-frame to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer models. This study compares functional, transcriptional, and pharmacological properties of additional ESR1 gene fusion events of both early stage (ESR1-NOP2) late stage (ESR1-YAP1 and ESR1-PCDH11x) breast cancers to gain a better understanding of therapeutic resistance and metastasis. Understanding the role of ESR1 fusions in inducing metastasis is critical, since the primary cause of death in breast cancer patients is through metastasis to distant sites.
Methods. RNA-seq screens identified ESR1 fusions from early and late stage, endocrine therapy resistant breast tumor samples. Functional experiments were conducted using ER+ breast cancer cell lines, xenograft, and PDX models to test the ability of ESR1 fusions to induce therapeutic resistance and metastasis. ChIP-seq and RNA-seq were performed to examine transcriptional properties and differential gene expression induced by the fusions which directed subsequent pharmacological experiments with a CDK4/6 inhibitor.
Results. ESR1-YAP1 and ESR1-PCDH11x promoted estrogen-independent and fulvestrant-resistant growth in vitro and induced greater tumor growth and increased metastatic capacity to the lungs of xenografted mice. In contrast, the ESR1-NOP2 fusion was sensitive to low estrogen conditions in vitro, and did not promote tumor growth. RNA-seq profiling revealed E2F targets pathway as the most highly enriched pathway induced by the ESR1 fusions. IHC revealed higher levels of pRb in ESR1-YAP1 and ESR1-PCDH11x xenograft tumors and subsequent CDK4/6 inhibition completely blocked tumor growth in an ESR1-YAP1 PDX model. Integrating RNA-seq with ChIP-seq data, we discovered a set of EMT and metastasis genes bound by all ESR1 fusions and WT-ER, but whose expression was strongly and uniquely up-regulated only by the ESR1-YAP1 and ESR1-PCDH11x fusions. These studies also revealed gained sites bound only by the ESR1-YAP1 and ESR1-PCDH11x fusions, not bound by WT-ER nor ESR1-NOP2. Genes mapping to these sites have a role in metastatic biology and were highly up-regulated by the YAP1 and PCDH11x fusions, potentially mediated by long range transcriptional activation.
Conclusion. ESR1-YAP1 and ESR1-PCDH11x are driver fusions that occur in drug-resistant, advanced stage breast cancer and are a new class of recurrent somatic mutation that can cause acquired endocrine therapy resistance, yet can be treated with CDK4/6 inhibition. These driver fusions also confer increased metastatic ability through their ability to drive expression of genes that contribute to EMT and metastasis. In contrast, ESR1-NOP2 did not produce functional protein and appears to be a passenger event. These studies may provide pre-clinical rationale for targeting ESR1 translocated breast tumors, since the presence of an ESR1 driver fusion places a patient in a therapeutic category where none of the currently available endocrine therapies are likely to be effective.
Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD8-03.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Shao
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Zhang
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Iglesia
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Anurag
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - P Singh
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - SM Kavuri
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Matsunuma
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Schmidt
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - Y Kosaka
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Crowder
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Hoog
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Phommaly
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Goncalves
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Ramalho
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - RM Rodrigues-Peres
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - W-C Lai
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - O Hampton
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - A Rogers
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - E Tobias
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - P Parikh
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Davies
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - V Suman
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - K Hunt
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Watson
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - KA Hoadley
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - CM Perou
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Maher
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
10
|
Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Abstract PD2-03: Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. We previously reported an alternative ESR1 somatic gain-of-function chromosomal translocation event in a patient presenting with aggressive, endocrine therapy resistant estrogen receptor (ER) positive disease, producing an in-frame fusion gene consisting of N-terminal ESR1 and the C-terminus of the Hippo pathway coactivator YAP1 (ESR1-YAP1). We recently identified another ESR1 fusion through RNA sequencing (RNA-seq) in advanced stage ER+ disease from a chest wall recurrence in a male patient that was refractory to multiple lines of treatment. Two examples of fusions discovered in primary breast cancer samples include ESR1 fused in-frame to C-terminal sequences from NOP2 (ESR1-NOP2), identified in a resistant cohort from a RNA-seq screen focused on 81 primary breast cancers from aromatase inhibitor clinical trials, and a second ESR1 fusion, fused in-frame to the entire coding sequence of POLH (ESR1-POLH), that was identified from RNA-seq analysis of 728 Cancer Genome Atlas breast samples. This current study extends our previous characterization of ESR1-YAP1 by comparing functional and pharmacological properties of these three additional ESR1 gene fusion events of both early stage and advanced breast cancers.
Methods. In vitro and in vivo experiments were conducted to test ESR1 fusions to induce therapeutic resistance, and metastasis. The transcriptional and binding properties of each fusion was also examined. Pharmacological inhibition with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, was utilized to assess drug sensitivity in ESR1 fusion containing breast cancer cells and in a patient derived xenograft (PDX) model expressing ESR1-YAP1 (WHIM18).
Results. The YAP1 and PCDH11x fusions conferred estrogen-independent and fulvestrant-resistant growth. Immunohistochemistry revealed significantly higher numbers of ER+ cells in lungs of mice xenografted with T47D cells expressing the YAP1 and PCDH11x fusions compared to YFP control, NOP2 and POLH fusions. Results from ChIP-seq and microarray studies suggest that these two fusions promote proliferation and metastasis through genomic action by binding estrogen response elements (ERE) and subsequent gene activation. We thereby define these fusions as “canonical” fusions compared to “non-canonical” NOP2 and POLH fusions, which demonstrated dramatically decreased genomic binding ability. The non-canonical fusions induced genes associated with basal-like breast cancer and promoted HER2, EGFR, and MAPK gene expression signatures in contrast to genes associated with cell cycle/proliferation induced by canonical fusions. The proliferative ability of canonical fusion-containing ER+ cells was inhibited by Palbociclib in a dose-dependent manner. In vivo WHIM18 tumors in mice fed with Palbociclib-containing chow demonstrated significantly reduced tumor volume, growth rate, and weight compared to tumors in mice on control chow.
Conclusions. In-frame ERE activating canonical fusions occur in end-stage drug resistant advanced breast cancer and can be added to ESR1 point mutations as a class of recurrent somatic mutation that may cause acquired resistance. Growth induced by these fusions can be antagonized by Palbociclib and is potentially clinically helpful.
Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD2-03.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Shao
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Zhang
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - M Iglesia
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - X He
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - Y Kosaka
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Schmidt
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Matsunuma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Crowder
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Hoog
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Phommaly
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Goncalves
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Ramalho
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - W-C Lai
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - O Hampton
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - A Rogers
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - E Tobias
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - P Parikh
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Davies
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - V Suman
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - K Hunt
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - M Watson
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - KA Hoadley
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - X Chen
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - CM Perou
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Maher
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
11
|
Ramalho S, Moura A, Gambaruto AM, Sequeira A. Sensitivity to outflow boundary conditions and level of geometry description for a cerebral aneurysm. Int J Numer Method Biomed Eng 2012; 28:697-713. [PMID: 25364846 DOI: 10.1002/cnm.2461] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Revised: 10/14/2011] [Accepted: 12/06/2011] [Indexed: 06/04/2023]
Abstract
Mathematical models, namely the flow boundary conditions, as well as the detail of the bounding geometry, can highly influence the computed flow field. In this work, an anatomically realistic portion of cerebral vasculature with a saccular aneurysm, and its geometric idealisation, are considered. The importance of the geometric description, namely including the side branches or modelling them as holes in the main vessel, is studied. Several approaches to prescribe the outflow boundary conditions at the side branches are analysed, including the traction-free condition, zero velocity (hence neglecting the side-branch), and the coupling with simple zero-dimensional and one-dimensional models. Results of the effects of outflow boundary modelling choice on computed haemodynamic parameters are used to identify appropriateness of the models based on the physical interpretation. Estimated range of error-bars associated to outflow boundary model choice and the level of geometric details are presented for patient-specific computational haemodynamics, and can serve as invitation for future studies. The zero-dimensional and one-dimensional models are shown to provide good representations of the side branches in the case of the clipped geometry.
Collapse
Affiliation(s)
- S Ramalho
- Dept. of Mathematics and CEMAT/IST, Instituto Superior Técnico, Technical University of Lisbon, Av. Rovisco Pais 1, 1049-001, Lisboa, Portugal
| | | | | | | |
Collapse
|
12
|
Slobodník J, Ramalho S, van Baar BL, Louter AJ, Brinkman UA. Determination of microcontaminants in sediments by on-line solid-phase extraction-gas chromatography-mass spectrometry. Chemosphere 2000; 41:1469-1478. [PMID: 11057585 DOI: 10.1016/s0045-6535(99)00526-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Two simple and straightforward analytical procedures for the screening of sediment samples are reported. They involve extraction with ethyl acetate or methanol and subsequent analysis by means of gas chromatography-mass spectrometry (GC-MS) using large-volume injection (LVI) or solid-phase extraction (SPE). The latter, which was originally developed for the analysis of aqueous samples, can be used without any modification. In general, 10 ml of organic solvent were added to 2 g of sediment, and the mixture was shaken and allowed to stand overnight. The methanolic extracts were then diluted in water and subjected to preconcentration and analysis using on-line SPE-GC-MS. The ethyl acetate extracts were injected directly into the GC using LVI. Both methods were used for the detection and identification of microcontaminants during a monitoring study of the river Nitra (Slovak Republic). They included polyaromatic hydrocarbons (PAHs), chlorofluorohydrocarbons, alkoxylated and alkylated phenols and benzothiazole derivatives. Semi-quantitative profiles of the contaminants were constructed and provisionally interpreted. The results indicate that SPE-GC-MS, and also LVI-GC-MS, have good potential for a rapid screening of sediment samples and the identification of microcontaminants. The analytical procedures pose no problems, and the on-line set-up is user-friendly.
Collapse
Affiliation(s)
- J Slobodník
- Department of Analytical Chemistry, Free University, Amsterdam, The Netherlands.
| | | | | | | | | |
Collapse
|